195 related articles for article (PubMed ID: 19553802)
1. Combination therapy using the small interfering RNA bevasiranib.
Singerman L
Retina; 2009 Jun; 29(6 Suppl):S49-50. PubMed ID: 19553802
[TBL] [Abstract][Full Text] [Related]
2. Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases.
Hohman TC
Retina; 2009 Jun; 29(6 Suppl):S51-3. PubMed ID: 19553804
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy for age-related macular degeneration.
Patel S
Retina; 2009 Jun; 29(6 Suppl):S45-8. PubMed ID: 19553801
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
5. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ziemssen F; Heiduschka P; Schraermeyer U;
Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
[No Abstract] [Full Text] [Related]
6. Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD.
Cashman SM; Bowman L; Christofferson J; Kumar-Singh R
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3496-504. PubMed ID: 16877421
[TBL] [Abstract][Full Text] [Related]
7. Strategies for inhibiting vascular endothelial growth factor.
Kaiser PK
Retina; 2009 Jun; 29(6 Suppl):S15-7. PubMed ID: 19553789
[TBL] [Abstract][Full Text] [Related]
8. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
9. Rationale for combination therapy in age-related macular degeneration.
Spaide RF
Retina; 2009 Jun; 29(6 Suppl):S5-7. PubMed ID: 19553803
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy in the anti-VEGF era.
Fine HF
Br J Ophthalmol; 2007 Jun; 91(6):707-8. PubMed ID: 17510474
[TBL] [Abstract][Full Text] [Related]
11. [Antivasoproliferative agents in ophthalmology].
Ambresin A; Zografos L; Mantel I
Rev Med Suisse; 2010 Jan; 6(231):51-4. PubMed ID: 20196434
[TBL] [Abstract][Full Text] [Related]
12. VEGF and age-related macular degeneration.
McKay GJ; Silvestri G; Orr N; Chakravarthy U; Hughes AE
Ophthalmology; 2009 Jun; 116(6):1227.e1-3. PubMed ID: 19486801
[No Abstract] [Full Text] [Related]
13. Anti-Vascular Endothelial Growth Factor Injection for Exudative Age-related Macular Degeneration in Patients with Vitreo-Macular Traction.
Querques G
Am J Ophthalmol; 2009 Feb; 147(2):375-6; author reply 376-7. PubMed ID: 19166716
[No Abstract] [Full Text] [Related]
14. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
Tuñón J; Ruiz-Moreno JM; Martín-Ventura JL; Blanco-Colio LM; Lorenzo O; Egido J
Surv Ophthalmol; 2009; 54(3):339-48. PubMed ID: 19422962
[TBL] [Abstract][Full Text] [Related]
15. Combination angiostatic therapies: current status.
Peyman GA; Fiscella R; Conway M
Retina; 2009 Jun; 29(6 Suppl):S18-20. PubMed ID: 19553790
[TBL] [Abstract][Full Text] [Related]
16. [Unspecific effects of certain siRNA molecules used in the treatment of age related macular degeneration].
Ebbesen M; Bek T; Pedersen FS; Jensen TG
Ugeskr Laeger; 2010 Sep; 172(36):2457-9. PubMed ID: 20825735
[TBL] [Abstract][Full Text] [Related]
17. Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment.
Busch T
Retina; 2009 Jun; 29(6 Suppl):S36-8. PubMed ID: 19553798
[TBL] [Abstract][Full Text] [Related]
18. Pathology beyond neovascularization: new targets in age-related macular degeneration.
Heier JS
Retina; 2009 Jun; 29(6 Suppl):S39-41. PubMed ID: 19553799
[TBL] [Abstract][Full Text] [Related]
19. Anti-macular degeneration agents.
Rothen M; Jablon E; Monares G; Fontal MR; Alfaro DV
Ophthalmol Clin North Am; 2005 Dec; 18(4):561-7. PubMed ID: 16314219
[TBL] [Abstract][Full Text] [Related]
20. Age-related macular degeneration.
Brucker AJ
Retina; 2009 Jun; 29(6 Suppl):S2-4. PubMed ID: 19553791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
